Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes

This study has been completed.
Sponsor:
Collaborators:
Kaiser Permanente
Department of Epidemiology at University of Pennsylvania
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01637935
First received: July 7, 2012
Last updated: December 9, 2015
Last verified: December 2015

July 7, 2012
December 9, 2015
July 2004
August 2014   (final data collection date for primary outcome measure)
Incident Diagnosis of Bladder Cancer (10-year Analysis) [ Time Frame: January 1, 1997 to December 31, 2012 ] [ Designated as safety issue: Yes ]
Incident bladder cancers were identified from January 1, 1997 to December 31, 2012.
  • Number of Participants With Newly Diagnosed Bladder Cancer [ Time Frame: January 1, 1997 to December 31, 2010. ] [ Designated as safety issue: No ]
    Bladder cancers were identified from the KPNC cancer registry from January 1, 1997 to December 31, 2010. This was supplemented by case identification through surveillance of electronic pathology reports within KPNC for the period from January 1, 2005 to December 31, 2010.
  • Incident Diagnosis of Bladder Cancer [ Time Frame: January 1, 1997 to December 31, 2010. ] [ Designated as safety issue: No ]
    Incident bladder cancers were identified from the KPNC cancer registry from January 1, 1997 to December 31, 2010. This was supplemented by case identification through surveillance of electronic pathology reports within KPNC for the period from January 1, 2005 to December 31, 2010. Incidence is reported as the number of newly diagnosed cases of bladder cancer per 100,000 person years. The 95% confidence interval was calculated using the Poisson method.
Complete list of historical versions of study NCT01637935 on ClinicalTrials.gov Archive Site
  • Incident Diagnosis of Bladder Cancer by Time Since Starting Pioglitazone (10 Year Analysis) [ Time Frame: January 1, 1997 to December 31, 2012 ] [ Designated as safety issue: Yes ]
  • Incident Diagnosis of Bladder Cancer by Duration of Pioglitazone Therapy (10 Year Analysis) [ Time Frame: January 1, 1997 to December 31, 2012 ] [ Designated as safety issue: Yes ]
  • Incident Diagnosis of Bladder Cancer by Cumulative Dose of Pioglitazone (10 Year Analysis) [ Time Frame: January 1, 1997 to December 31, 2012 ] [ Designated as safety issue: Yes ]
  • Stage of Bladder Cancer (10 Year Analysis) [ Time Frame: January 1, 1997 to December 31, 2012 ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes
Cohort Study of Pioglitazone and Bladder Cancer in Patients With Diabetes
To assess the potential association between pioglitazone and bladder cancer compared with non-pioglitazone users among patients with type 2 diabetes mellitus.

Following guidance from the United States Food and Drug Administration (FDA) and European Medicines Agency, the University of Pennsylvania and Kaiser Permanente Northern California (KPNC) designed and conducted this study using the KPNC database to assess the potential association between pioglitazone and bladder cancer among patients with type 2 diabetes mellitus.

The study was conducted over the course of 10 years, with a series of interim analyses undertaken during this period and provided to the sponsor (Takeda) and the appropriate regulatory agencies.

In 2011, the planned 5-year interim analysis of this study was published in Diabetes Care. That report included data from 1 January 1997 to 30 April 2008. Following reporting of these data, there was a request from the FDA for an additional fourth interim analysis at 8 years including data from 1 January 1997 to 31 December 2010.

In August 2011 the FDA requested inclusion of a sensitivity analysis to assess change of cohort entry criteria to minimize left censoring of exposure. Included in the FDA request was a duration analysis for other antidiabetic medications.

In August 2014, the final 10-year analyses were completed and submitted to the sponsor and regulatory agencies.

Interim results previously posted on clinicaltrials.gov are available in the public archive

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

The study was conducted within Kaiser Permanente Northern California (KPNC), which provides comprehensive healthcare services to approximately 3.2 million members. The source population was identified from the KPNC diabetes registry, which was first constructed in 1993 and has been updated annually since then. The registry identifies patients primarily from four data sources: primary hospital discharge diagnoses of diabetes mellitus (since 1971); two or more outpatient visit diagnoses of diabetes (since 1995); any prescription for a diabetes-related medication (since 1994); or any record of an abnormal hemoglobin A1c (HbA1c) test (>6.7%) (since 1991).

The diabetes registry gathers data from a variety of KPNC electronic medical records (EMR) to build and follow the registry cohort across time. These data include cancer registries, pharmacy records, laboratory records, and inpatient and outpatient medical diagnoses.

  • Diabetes
  • Bladder Cancer
Drug: Pioglitazone
Pioglitazone tablets.
Other Name: Actos
  • Pioglitazone exposed group
    Defined as those patients having filled at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone group may also have exposure to other diabetic medications
    Intervention: Drug: Pioglitazone
  • Pioglitazone unexposed group
    Defined as patients who did not fill at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone unexposed group may have been exposed to other diabetic medications. This group also included diabetic patients without any diabetic medications.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
193099
August 2014
August 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The study cohort included both patients with an established diagnosis of diabetes mellitus prior to January 1, 1997 and those who were newly diagnosed prior to December 31, 2002. Patients were eligible for the study cohort if they met any of the following criteria:

    1. As of January 1, 1997 they had been diagnosed with diabetes mellitus, were age 40 or older and were members of KPNC,
    2. They had been diagnosed with diabetes mellitus, reached age 40 between January 1, 1997 and December 31, 2002 and were KPNC members on their 40th birthday, or
    3. Had diabetes mellitus and were age 40 or older when they joined KPNC between January 1, 1997 and December 31, 2002.

      Exclusion Criteria:

  • Diagnosis of bladder cancer recorded in the KPNC cancer registry prior to entry to the cohort or within 6 months of entry into KPNC.
Both
40 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01637935
01-03-TL-OPI-524, U1111-1132-3482
No
Not Provided
Not Provided
Takeda
Takeda
  • Kaiser Permanente
  • Department of Epidemiology at University of Pennsylvania
Not Provided
Takeda
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP